» Articles » PMID: 28212898

Low Serum Iron is Associated with High Serum Intact FGF23 in Elderly Men: The Swedish MrOS Study

Overview
Journal Bone
Date 2017 Feb 19
PMID 28212898
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fibroblast growth factor (FGF23) is a protein that is produced by osteoblasts and osteocytes. Increased serum levels of FGF23 have been associated with increased risks of osteoporotic fractures and cardiovascular disease, particularly in participants with poor renal function. Serum iron (Fe) has been suggested as a regulator of FGF23 homeostasis.

Objective: To determine whether Fe and iron status are determinants of the levels of intact FGF23 (iFGF23) in elderly men.

Methods: The MrOS study is a population-based study of elderly men (N=1010; mean age, 75.3years; range, 69-81years). The levels of Fe, transferrin saturation (TS), and ferritin were evaluated in relation to the serum concentrations of iFGF23 before and after adjustments for confounders.

Results: TS <15% was found in 3.5% (34/977) of the participants, who had a higher median level iFGF23 compared with the remaining subjects (47.4μmol/L vs. 41.9μmol/L, p=0.008). The levels of iFGF23 correlated negatively (un-adjusted) with the levels of Fe (r=-0.17, p<0.001), TS (r=-0.16, p<0.001) and serum ferritin (r=-0.07, p=0.022). In addition, in participants with estimated glomerular filtration rate eGFRCystatin C>60mL/min, the levels of iFGF23 correlated (age-adjusted) negatively with the levels of Fe (r=-0.15, p<0.001) and TS (r=-0.17, p<0.001). The level of iFGF23 correlated positively (un-adjusted) with lumbar spine bone mineral density (BMD) (r=0.14, p<0.001), total body BMD (r=0.11, p=0.001), and total hip BMD (r=0.09, p=0.004). The corresponding correlations, when adjusted for age, weight, and height were: r=0.08, p=0.018; r=0.05, p=0.120; and r=0.02, p=0.624, respectively. No associations were found between BMD and the levels of Fe or TS. Multiple step-wise linear regression analyses [adjusting for age, body mass index (BMI), comorbidity index, cystatin C, C-reactive protein (hs-CRP), serum vitamin D 25-OH (25OHD), phosphate, calcium, parathyroid hormone (PTH), erythropoietin, hemoglobin, lumbar spine BMD, apolipoprotein B/A1 ratio] were performed in three separate models with Fe, TS or ferritin as potential explanatory variables. Fe and TS, but not ferritin, were independent predictors of iFGF23 level (standardized β-values: -0.10, p<0.001; -0.10, p<0.001; and -0.05, p=0.062, respectively).

Conclusion: Low levels of Fe in elderly men are associated with high levels of iFGF23, independently of markers of inflammation and renal function, suggesting an iron-related pathway for FGF23 regulation.

Citing Articles

Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.

Carullo N, Sorbo D, Faga T, Pugliese S, Zicarelli M, Costa D Int J Mol Sci. 2024; 25(23).

PMID: 39684548 PMC: 11641783. DOI: 10.3390/ijms252312838.


Intact FGF23 and Markers of Iron Homeostasis, Inflammation, and Bone Mineral Metabolism in Acute Pediatric Infections.

Papastergiou E, Rallis D, Papagianni A, Cholevas V, Katzilakis N, Siomou E Biology (Basel). 2024; 13(9).

PMID: 39336155 PMC: 11428972. DOI: 10.3390/biology13090728.


Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.

Christodoulou M, Aspray T, Piec I, Fraser W, Schoenmakers I Age Ageing. 2024; 53(5).

PMID: 38770543 PMC: 11106582. DOI: 10.1093/ageing/afae096.


Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations.

Bosman A, Ratsma D, van der Eerden B, Zillikens M JBMR Plus. 2023; 7(10):e10790.

PMID: 37808399 PMC: 10556273. DOI: 10.1002/jbm4.10790.


Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.

Egli-Spichtig D, Hamid A, Pastor Arroyo E, Ketteler M, Wiecek A, Rosenkranz A Clin Kidney J. 2023; 16(10):1622-1633.

PMID: 37779856 PMC: 10539220. DOI: 10.1093/ckj/sfad040.